Allergan launches Taytulla softgel contraceptive

DUBLIN — Allergan on Thursday announced the launch of its Taytulla norethindrone acetate and ethinyl estradiol capsules and ferrous fumarate capsules, 1mg/20mcg), the first softgel capsule oral contraceptive. 

 

"As a leader in women's healthcare, we are pleased to bring to market Taytulla, the first and only oral contraceptive in a softgel capsule, providing women with an important new and effective option to consider with their healthcare providers," Allergan chief commercial officer Bill Meury said. "The patented softgel technology of Taytulla was designed with absorption and solubility in mind, contains 20 mcg of estrogen, and offers women pregnancy prevention with short, light periods."

 

TAYTULLA will be commercially available in blister cards containing 24 oval, opaque, pale pink (active) soft gelatin capsules, each containing 1 mg norethindrone acetate and 20 mcg ethinyl estradiol, and 4 oval, opaque, maroon (nonhormonal placebo) capsules containing iron.